Two funds that will help ensure a brighter outlook for care homes
Two listed real-estate investment trusts in the care-home sector look attractively valued and offer a decent income too, says Max King.
The two listed real-estate investment trusts (Reits) that own care homes, Impact Healthcare (LSE: IHR), with £360m of assets, and Target Healthcare (LSE: THRL) with £520m, have come through the Covid-19 crisis well. The stocks have fallen by 6% in six months. The former trades on a 4% discount to net asset value (NAV) and the latter a 5% premium. They both yield over 6%. The result is attractive but not too-good-to-be-true valuations.
The cost of care for the elderly has become a burning political issue. In 2019, £16.5bn was spent providing for around 450,000 elderly residents of 12,000 care homes. About 3.2 million people in Britain are over 80 and that number is expected to grow steadily over the next 20 years. Demand for beds in care homes is rising. Accountancy group Grant Thornton projects long-term growth of about 1.8% per annum, which, with existing homes full, requires new capacity.
Learning the lessons of the 1990s
Capacity reached 550,000 in 1997 after a decade of strong growth largely as the result of the construction of purpose-built, single-storey, specialist homes by listed private-sector companies. The new Blair government, however, disliked the idea that investors and entrepreneurs, such as Duncan Bannatyne, were prospering at public expense, since most of the places were filled by local authorities and the NHS. So they squeezed the providers by limiting the reimbursement from the Treasury, while other government measures raised staff costs. Capacity fell by 20% over the next decade, which ought to make the private sector wary of being asked to help solve the crisis in elderly care all over again.Fortunately, Impact and Target are not getting carried away. The business model of both is to own the homes but rent them to specialist operators. The number of beds owned by Impact has more than doubled to 5,600 in three years and the number of properties has nearly doubled to 104. But expansion has been funded by equity, not debt. Eleven tenants provide a contracted rent of nearly £30m, resulting in a return on capital of 8.8%. All of the rent due in the year to date has been received.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Just six homes had some residents testing positive for Covid-19, and all were free of it by the end of July. Occupancy levels dropped by 8% between March and the end of June but have now started to recover. Tenants’ costs rose sharply as a result of the increased expense of agency staffing, protective equipment and cleaning, but are now coming down. With an average increase in weekly fees of 12.5% in the year to April, the tenants can comfortably afford their steadily increasing rents. Only a handful of Target’s 71 homes have been affected by Covid-19, with the infection rate falling from a peak of 3.2% of its 4,925 beds to under 0.3%. About 96% of its rents for the second quarter have been received. Despite this, like-for-like rental income increased 0.4% in the last quarter, allowing a marginal increase in NAV even after paying a quarterly dividend. Meanwhile, £43.6m of rental income, expected to increase by 8.7% this year, provides a return on capital very similar to Impact. Target has net debt of around 20% of gross assets, so an equity issue to fund further expansion is likely.
Target looks more expensive but this may reflect the quality of its portfolio: larger than Impact’s and all purpose-built. With fees rising faster than costs, the dividends of both look likely to increase steadily. Both shares look attractive for yield and capital growth but the potential for political interference, well-meaning or not, should not be ignored.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Max has an Economics degree from the University of Cambridge and is a chartered accountant. He worked at Investec Asset Management for 12 years, managing multi-asset funds investing in internally and externally managed funds, including investment trusts. This included a fund of investment trusts which grew to £120m+. Max has managed ten investment trusts (winning many awards) and sat on the boards of three trusts – two directorships are still active.
After 39 years in financial services, including 30 as a professional fund manager, Max took semi-retirement in 2017. Max has been a MoneyWeek columnist since 2016 writing about investment funds and more generally on markets online, plus occasional opinion pieces. He also writes for the Investment Trust Handbook each year and has contributed to The Daily Telegraph and other publications. See here for details of current investments held by Max.
-
Can you afford to retire in 2025?
From interest rates and inflation to tax changes, there are plenty of factors to consider if you plan to retire next year – here is how to prepare.
By Marc Shoffman Published
-
8 of the best properties for sale near ski slopes
The best properties for sale near ski slopes – from a luxury cabin in Geilo, one of Norway’s premier ski resorts, to a large chalet in Valais, Switzerland
By Natasha Langan Published
-
Warren Buffet invests in Domino’s – should you buy?
What makes Domino's a compelling investment for Warren Buffet's Berkshire Hathaway, and should you buy the UK-listed takeaway pizza chain?
By Dr Matthew Partridge Published
-
Should you buy JPMorgan's top emerging market trust?
The JPMorgan Emerging Markets Trust fund has outperformed its benchmark over the long term and offers good value
By Max King Published
-
4Imprint makes a strong impression – should you buy?
4Imprint, a specialist in marketing promotional products, is the leader in a fragmented field
By Dr Mike Tubbs Published
-
Invest in Glencore: a cheap play on global growth
Glencore looks historically cheap, yet the group’s prospects remain encouraging
By Rupert Hargreaves Published
-
Should you invest in Trainline?
Ticket seller Trainline offers a useful service – and good prospects for investors
By Dr Matthew Partridge Published
-
Two investment trusts riding the AI boom
Remain invested in investment trusts despite high valuations, as computing breakthroughs are likely to change the world
By Max King Published
-
Key takeaways from the MoneyWeek Summit 2024: Investing in a dangerous world
If you couldn’t get a ticket to MoneyWeek’s summit, here’s an overview of what you missed
By MoneyWeek Published
-
DCC: a top-notch company going cheap
DCC has a stellar long-term record and promising prospects. It has been unfairly marked down
By Jamie Ward Published